Urothelial Cancer Drugs Market Size, Share & Trends Report

Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023

  • Report ID: GVR-2-68038-429-1
  • Number of Pages: 86
  • Format: Electronic (PDF)

Table of Contents

Chapter 1 Research Methodology
                  1.1. Information Procurement
                  1.2. Information or Data Analysis
                      1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                  3.1. Disease Primer
                  3.2. Epidemiology
Chapter 4 Global Urothelial Cancer Drugs Market Overview
                  4.1 Market by Treatment Class
                  4.2 Market Size and Forecast 2017- 2023
                  4.3 Market Share Distribution, by Company 2017- 2023
                  4.4 Market Dynamics and Brand Strategies
                  4.5 Patent Expiry Analysis
                  4.6 Urothelial Cancer Market: Drivers and Restraints
                      4.6.1 Drivers
                      4.6.2 Challenges
                  4.7 M&A, Deal Landscape (2013-2018 YTD)
                      4.7.1 Mergers & Acquisitions
                      4.7.2 Deals Landscape
                  4.8 Emerging Markets
                  4.9 Reimbursement Scenario
                  4.10 Urothelial Cancer Sector SWOT
Chapter 5 Urothelial Cancer Drugs Market: Pipeline Intelligence
                  5.1. Pipeline Landscape
                      5.1.1 Leading Drugs in Development
                      5.1.2 Key R&D Trends
                  5.2 Pipeline Landscape
                      5.2.1 Late-Stage Pipeline and Sales Forecast
                      5.2.2 Profiles of Disruptive Drugs
                  5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
                  6.1 Merck
                      6.1.1 Company Overview
                      6.1.2 Current Product Portfolio
                      6.1.3 Product Forecast Sales Through 2023
                      6.1.4 Strategic Initiatives
                          6.1.4.1 Key Company News Flow
                      6.1.5 Pipeline Analysis & Overview
                      6.1.6 SWOT
                  6.2 Roche
                      6.2.1 Company Overview
                      6.2.2 Current Product Portfolio
                      6.2.3 Product Forecast Sales Through 2023
                      6.2.4 Strategic Initiatives
                          6.2.4.1 Key Company News Flow
                          6.2.4.2 Catalysts & Events Calendar
                      6.2.5 Pipeline Analysis & Overview
                      6.2.6 SWOT
                  6.3 Bristol-Myers Squibb
                      6.3.1 Company Overview
                      6.3.2 Current Product Portfolio
                      6.3.3 Product Forecast Sales Through 2023
                      6.3.4 Strategic Initiatives
                          6.3.4.1 Key Company News Flow
                      6.3.5 Pipeline Analysis & Overview
                      6.3.6 SWOT
                  6.4 AstraZeneca
                      6.4.1 Company Overview
                      6.4.2 Current Product Portfolio
                      6.4.3 Product Forecast Sales Through 2023
                      6.4.4 Strategic Initiatives
                          6.4.4.1 Key Company News Flow
                          6.4.4.2 Catalysts & Events Calendar
                      6.4.5 Pipeline Analysis & Overview
                      6.4.6 SWOT
                  6.5 Pfizer
                      6.5.1 Company Overview
                      6.5.2 Current Product Portfolio
                      6.5.3 Product Forecast Sales Through 2023
                      6.5.4 Strategic Initiatives
                          6.5.4.1 Key Company News Flow
                          6.5.4.2 Catalysts & Events Calendar
                      6.5.5 Pipeline Analysis & Overview
                      6.5.6 SWOT
Chapter 7 Market Outlook
                  7.1 What the Future Holds
                  7.2 The Winners and Losers
                      7.2.1 Winners
                      7.2.2 Losers
                  7.3 Emerging Companies & Technology Platforms
                  7.4 The Road Ahead


List of Tables

TABLE 1 Incidence Rate per 100,000 in Seven Major Markets
TABLE 2 Marketed Drugs for Urothelial Cancer
TABLE 3 Sales Performance by Treatment Type, 2017 - 23
TABLE 4 Sales Performance by Market, in $ million, 2017 - 2023
TABLE 5 Patents Expiry for Current Urothelial Cancer Drugs
TABLE 6 R&D Pipeline Overview
TABLE 7 Late-Stage Pipeline
TABLE 8 Epacadostat
TABLE 9 Erdafitnib
TABLE 10 Cyramza
TABLE 11 Pipeline Forecast
TABLE 12 Merck Sales Forecast, 2017 - 2023
TABLE 13 Merck Pipeline
TABLE 14 Roche Sales Forecast, 2017 - 2023
TABLE 15 Roche Pipeline
TABLE 16 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
TABLE 17 Bristol-Myers Squibb Pipeline
TABLE 18 Astrazeneca Sales Forecast, 2017 - 2023
TABLE 19 AstraZeneca Pipeline
TABLE 20 Pfizer Sales Forecast, 2017 - 2023
TABLE 21 Pfizer Pipeline


List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Urothelial Cancer Drugs Market Share, by Treatment Type, 2017 & 23
FIG. 8 Regional Market Size, 2017 & 2023
FIG. 9 U.S. Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 10 U.K. Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 11 Germany Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 12 Italy Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 13 Spain Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 14 France Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 15 Japan Urothelial Cancer Drugs Market, $ million (2017 - 23)
FIG. 16 Market Shares Distribution, 2017&2023
FIG. 17 Urothelial Cancer SWOT
FIG. 18 Urothelial Cancer Pipeline Distribution
FIG. 19 Merck UC Sales Forecast
FIG. 20 Merck SWOT Analysis
FIG. 21 Roche UC Sales Forecast
FIG. 22 Roche SWOT Analysis
FIG. 23 Bristol-Myers Squibb UC Sales Forecast
FIG. 24 Bristol-Myers Squibb SWOT Analysis
FIG. 25 AstraZeneca UC Sales Forecast
FIG. 26 AstraZeneca SWOT Analysis
FIG. 27 Pfizer UC Sales Forecast
FIG. 28 Pfizer SWOT Analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.